| Generic name |
Idoxuridine
|
| Brand Names/Synonyms |
5IUDR; 5idu; Allergan 201; Allergan 211; Antizona; CCRIS 2827; Dendrid; Emanil; Heratil; Herpe-Gel; Herpes-Gel; Herpesil; Herpid; Herpidu; Herplex; Herplex Liquifilm; ID2; IDU; IDUR; IUDR; Idexur; Idossuridina [Dcit]; Idoxene; Idoxuridin; Idoxuridina [Inn-Spanish]; Idoxuridine; Idoxuridine [Usan:Ban:Inn:Jan]; Idoxuridinum [Inn-Latin]; Idu Oculos; Iducher; Idulea; Iduridin; Iduviran; Iododeoxyridine; Iodoxuridine; Joddeoxiuridin; Kerecid; NSC 39661; Ophthalmadine; SK&F 14287; Spectanefran; Stoxil; Synmiol; Virudox |
| Indication |
For use in keratoconjunctivitis and keratitis caused by herpes simplex virus |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
In chemical structure idoxuridine closely approximates the configuration of thymidine, one of the four building blocks of DNA (the genetic material of the Herpes virus). As a result, idoxuridine is able to replace thymidine in the enzymatic step of viral replication or "growth". The consequent production of faulty DNA results in a pseudostructure which cannot infect or destroy tissue. In short, by pre-empting a vital building block in the genetic material of the Herpes simplex virus, Herplex-D topical solution destroys the infective and destructive capacity of the viral material. The virus infected cell may only be attacked during the period of active synthesis of DNA. This occurs early in the development of the Herpes simplex lesion, but at different times in different cells. Therefore, ideally, the affected area should remain saturated with the antiviral agent. |
| Mechanism Of Action |
Idoxuridine acts as an antiviral agent against DNA viruses by inhibiting thymidilate phosphorylase and viral DNA polymerases. The effect of Idoxuridine results in the inability of the virus to reproduce or to infect/destroy tissue. |
Idoxuridine News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
Opthalmic drops; Ophthalmic ointment |
| Drug_Category |
Antivirals; Antivirals; Nucleic Acid Synthesis Inhibitors; ATC:D06BB01; ATC:J05AB02; ATC:S01AD01 |
| Absorption |
Systemic absorption is unlikely following ocular administration even when nasolacrimal secretions are swallowed, since vidarabine is rapidly deaminated in the gastrointestinal tract |
| Interactions |
Other medicines - Although certain medicines should not be used together at all, in other cases
two different medicines may be used together even if an interaction might occur. In these cases,
your doctor may want to change the dose, or other precautions may be necessary.
When you are using idoxuridine, it is especially important that your health care professional know
if you are using the following:
Eye product containing boric acid. Boric acid may interact with the idoxuridine preparation causing
a gritty substance to form or may interact with the preservative in the idoxuridine preparation
causing a toxic effect in the eye.
|
| Toxicity |
hypersensitivity or increased sensitivity of eyes to light LD50=3080 mg/kg (orally in mice) |
| Organisms Affected |
Not Available |
| Chemical IUPAC Name |
1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-iodo-1H-pyrimidine-2,4-dionein |
| Chemical Formula |
C9H11IN2O5 |
| Molecular Weight |
354.099 g/mol |
| Smiles String |
C1C(C(OC1N2C=C(C(=O)NC2=O)I)CO)O |
| Melting Point |
164-166°C |
| Water Solubility |
<0.01 g/100 mL |
| State |
Solid |
| LogP/Hphobicity |
-0.253 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Idoxuridine is rapidly inactivated by deaminases or nucleotidases. |
| Half Life |
Not Available |
| Protein Binding [%] |
Not Available |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
http://www.drugs.com/cons/Idoxuridine.html |
| Drug Type |
Approved Drug |
| Accession No |
APRD00504 |
| CAS Registry Number |
54-42-2 |
| KEGG Compound ID |
C07046 |
| PubChem ID |
SID:371639 |
| PharmGKB ID |
PA449963 |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
2237187
|
